AMOEBA (EPA:ALMIB) - AMOÉBA announces the possible use of its substance for the treatment of one of the pathogens of field crops, rust

Transparency directive : regulatory news

01/07/2019 17:45

PRESS RELEASE

AMOÉBA announces the possible use of its substance for the treatment of one of
                      the pathogens of field crops, rust

Chassieu, July 1, 2019 - AMOÉBA (FR0011051598 - AMEBA), producer of a
biological biocide, still in the testing phase, capable of eliminating
bacterial risk in water and human wounds, and a biocontrol product for plant
protection, announces an efficacy of more than 85% of its amoeba lysate
Willaertia magna C2c Maky in planta against rust. Rust is a group of diseases
that are particularly damaging to field crops (soybeans, wheat, etc.).

Amoéba thus broadens its spectrum of action in biocontrol application by
demonstrating an in planta efficacy of more than 85% against bean rust used as
a rust model. The tests were carried out by an independent expert company,
according to a standard protocol. Rust is caused by the fungus Uromyces fabae,
a pathogen very different from the other germs (downy mildew of grapevine and
late blight of potato) on which the lysed amoeba has already demonstrated its
action in planta.

To date, there is no biocontrol product in the world for the treatment of
soybean rust or cereal rusts. The field crop market is by far the most
important fungicide market. For information, the fungicide market for cereals
in Europe is estimated at $2 billion dollars and $1 billion for the treatment
of soybean rust alone in Brazil.

This new demonstration of efficacy against one of the most fought diseases in
the world confirms the strategic dimension of biocontrol in the development of
the amoeba application portfolio.

"These new results show us that the product has a broad spectrum of action, but
the extent of it has yet to be defined. Using our amoeba lysed in field crops
could considerably expand our range of treatments. The challenge for us is now
to make the most of these advances as quickly as possible with external
partners," says Fabrice PLASSON, Chairman and CEO of Amoéba.

About AMOEBA:
Amoéba's ambition is to become a major player in the treatment of bacterial
risk in the fields of water, healthcare and plant protection. Our biological
solution is an alternative to chemical products widely used today. Amoéba is
currently focusing on the market of industrial cooling towers estimated at
EUR1.7Bn (1) on a global chemical biocide market for water treatment, evaluated
at EUR21Bn (2) and on the biocontrol market for plant protection estimated
globally at EUR1.6Bn (4). In the future, the Company is looking at developing
new applications such as chronic wound care, estimated at EUR 751 million (3)
in the USA. Sales of associated products with healthcare, biocides and crop
protection are subject to the Company being granted local regulatory market
authorizations.

The Company is currently in a trial phase for biocidal and plant protection
applications and does not market any products.
Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada
and in the United States, Amoéba is quoted on the compartment C of Euronext
Paris. The Company is a member of the BPIfrance Excellence network and is
eligible for the PEA-PME SME equity savings plan setup. More information on
www.amoeba-biocide.com.

(1) : Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013
(2) : Sources combined by Amoéba from water treaters, Freedonia, Eurostat et
      MarketsandMarkets
(3):  BCC Research, "Markets for Advanced Wound Management Technologies,"
      Wellesley, MA, 2017
(4):  Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts:

Amoéba
Valérie FILIATRE
General Manager
+33 (0)4 26 69 16 00
valerie.filiatre@amoeba-biocide.com

Investors Relations
Grégory BOSSON
Agence Calyptus
+33(0)1 53 65 37 90
gregory.bosson@calyptus.net

Medias relations
Constance LOZET
Agence Ekno
+33(0)7 78 41 19 70
constance.lozet@ekno.fr

Disclaimer
This press release contains certain forward-looking statements concerning
AMOEBA which are based on its own assumptions and hypothesis and on information
that are available to us. However, AMOEBA gives no assurance that the estimates
contained in such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the reference
document of AMOEBA filed with the French Financial Markets Authority (Autorité
des Marchés Financiers) on April 25, 2019 under number D19-0383 (a copy of
which is available on www.amoeba-biocide.com). The forward-looking statements
contained in this press release are also subject to risks not yet known to
AMOEBA or not currently considered material by AMOEBA. The occurrence of all or
part of such risks could cause actual results, financial conditions,
performance or achievements of AMOEBA to be materially different from such
forward-looking statements.

AMOEBA's latest news

28/03/2024 18:30

AMOEBA (EPA:ALMIB) - AMOÉBA announces the possible use of its substance for the treatment of one of the pathogens of field crops, rust

Transparency directive : regulatory news

AMOEBA's latest news

Other stories